Seres Therapeutics (MCRB) Enterprise Value (2014 - 2026)
Seres Therapeutics (MCRB) posted Enterprise Value of -$29.8 million for Q1 2026, up 34.81% sequentially from -$45.8 million in Q4 2025, and up 49.3% YoY from -$20.0 million in Q1 2025.
Seres Therapeutics (MCRB) Enterprise Value (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Enterprise Value for 13 years, with the latest figure at -$29.8 million in Q1 2026.
- Quarterly Enterprise Value rose 49.3% year-over-year to -$29.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.8 million (up 49.3% YoY) and the FY2025 annual result came in at -$45.8 million, down 48.62% from the prior year.
- Enterprise Value advanced to -$29.8 million in Q1 2026 per MCRB's latest filing, from -$45.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$29.8 million in Q1 2026 and troughed at -$342.8 million in Q1 2022.
- A 5-year average of -$128.9 million and a median of -$106.5 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 75.94% in 2024, then slumped 48.62% in 2025.
- Over 5 years, Enterprise Value stood at -$181.3 million in 2022, then advanced by 29.43% to -$128.0 million in 2023, then soared by 75.94% to -$30.8 million in 2024, then sank by 48.62% to -$45.8 million in 2025, then soared by 34.81% to -$29.8 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$29.8 million, -$45.8 million, and -$47.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Seres Therapeutics | 43.82 Mn | 43.82 Mn | - | -15.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.59 Mn |
| Mar 31, 2026 | -29.83 Mn |
| Dec 31, 2025 | -45.77 Mn |
| Sep 30, 2025 | -47.64 Mn |
| Jun 30, 2025 | -45.38 Mn |
| Mar 31, 2025 | -58.85 Mn |
| Dec 31, 2024 | -30.79 Mn |
| Sep 30, 2024 | -66.82 Mn |
| Jun 30, 2024 | -71.23 Mn |
| Mar 31, 2024 | -111.18 Mn |
| Dec 31, 2023 | -127.97 Mn |
| Sep 30, 2023 | -169.91 Mn |
| Jun 30, 2023 | -229.52 Mn |
| Mar 31, 2023 | -106.54 Mn |
| Dec 31, 2022 | -181.34 Mn |
| Sep 30, 2022 | -260.61 Mn |
| Jun 30, 2022 | -264.77 Mn |
| Mar 31, 2022 | -342.81 Mn |
| Dec 31, 2021 | -290.71 Mn |
| Sep 30, 2021 | -347.39 Mn |